Vontobel Holding Ltd. Has $1.15 Million Stake in DexCom, Inc. $DXCM

Key Points

• Vontobel Holding Ltd. reduced its stake in DexCom, Inc. by 33.3% in Q2, now holding 13,191 shares valued at approximately $1.15 million.
• Several institutional investors have increased their holdings in DexCom, with significant increases reported by Golden State Wealth Management LLC (211.2% growth) and Private Trust Co. NA (99.4% growth).
• Analysts have shown mixed sentiment, with target prices for DexCom ranging from $85 to $102 and a consensus rating of "Moderate Buy" based on 3 Strong Buy, 14 Buy, and 6 Hold ratings.

Vontobel Holding Ltd. decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 33.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,191 shares of the medical device company's stock after selling 6,575 shares during the quarter. Vontobel Holding Ltd.'s holdings in DexCom were worth $1,151,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Golden State Wealth Management LLC grew its position in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares during the period. Zions Bancorporation National Association UT bought a new position in shares of DexCom in the 1st quarter worth $27,000. Anderson Financial Strategies LLC bought a new position in shares of DexCom in the 1st quarter worth $37,000. Alpine Bank Wealth Management bought a new position in shares of DexCom in the 1st quarter worth $40,000. Finally, Private Trust Co. NA lifted its holdings in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after purchasing an additional 335 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares of the company's stock, valued at $8,417,840. This trade represents a 1.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the sale, the executive vice president directly owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock valued at $564,733 in the last 90 days. Insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on DXCM. Piper Sandler increased their target price on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Morgan Stanley increased their target price on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Citigroup cut their target price on DexCom from $105.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, October 7th. Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 30th. Finally, Truist Financial began coverage on DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $97.42.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $65.12 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The stock's fifty day simple moving average is $74.42 and its two-hundred day simple moving average is $77.72. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The stock has a market cap of $25.54 billion, a PE ratio of 45.22, a price-to-earnings-growth ratio of 1.37 and a beta of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. During the same period last year, the business earned $0.43 EPS. The business's revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.